Notice for bioequivalence testing of combination products to be made public in November

Published: 2010-03-16 06:59:00

Updated: 2010-03-16 06:59:00

The Notice designed to redefine the bioequivalence testing of combined preparations is likely to be delayed due to screening of the Office of Prime Minister and final confirmation of the commissioner of the Korea Food and Drug Administration.

The drug agency said the mandatory bioequivalence s...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK